Eledon Pharmaceuticals shares are trading lower. The company announced results from its ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation.
Portfolio Pulse from Benzinga Newsdesk
Eledon Pharmaceuticals announced results from its ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. This news has led to a decrease in the company's share price.
November 02, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eledon Pharmaceuticals' shares are trading lower following the announcement of results from its ongoing Phase 1b trial of tegoprubart.
The announcement of the results from the Phase 1b trial of tegoprubart, a drug being developed by Eledon Pharmaceuticals, has led to a decrease in the company's share price. This suggests that the market may have had negative reactions to the results, which could continue to impact the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100